MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592510 | Name: Aldophosphamide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aldophosphamide has apoptotic antitumor activity.

Chemical Structure

Aldophosphamide
Aldophosphamide
CAS#35144-64-0

Theoretical Analysis

MedKoo Cat#: 592510

Name: Aldophosphamide

CAS#: 35144-64-0

Chemical Formula: C7H15Cl2N2O3P

Exact Mass: 276.0197

Molecular Weight: 277.08

Elemental Analysis: C, 30.34; H, 5.46; Cl, 25.59; N, 10.11; O, 17.32; P, 11.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Aldophosphamide
IUPAC/Chemical Name
Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-, 3-oxopropyl ester
InChi Key
QMGUSPDJTPDFSF-UHFFFAOYSA-N
InChi Code
InChI=1S/C7H15Cl2N2O3P/c8-2-4-11(5-3-9)15(10,13)14-7-1-6-12/h6H,1-5,7H2,(H2,10,13)
SMILES Code
O=P(N(CCCl)CCCl)(N)OCCC=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 277.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Voelcker G. Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity. Anticancer Drugs. 2018 Jan;29(1):75-79. doi: 10.1097/CAD.0000000000000569. PubMed PMID: 29219879. 2: Voelcker G. Influence of the alkylating function of aldoifosfamide on the antitumor activity. Anticancer Drugs. 2017 Oct 3. doi: 10.1097/CAD.0000000000000569. [Epub ahead of print] PubMed PMID: 28984684. 3: Wang J, Wang YJ, Chen ZS, Kwon CH. Synthesis and evaluation of sulfonylethyl-containing phosphotriesters of 3'-azido-3'-deoxythymidine as anticancer prodrugs. Bioorg Med Chem. 2014 Nov 1;22(21):5747-56. doi: 10.1016/j.bmc.2014.09.046. Epub 2014 Sep 28. PubMed PMID: 25440502. 4: Parajuli B, Georgiadis TM, Fishel ML, Hurley TD. Development of selective inhibitors for human aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide cytotoxicity. Chembiochem. 2014 Mar 21;15(5):701-12. PubMed PMID: 24677340; PubMed Central PMCID: PMC4043872. 5: Parajuli B, Fishel ML, Hurley TD. Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells. J Med Chem. 2014 Jan 23;57(2):449-61. doi: 10.1021/jm401508p. Epub 2014 Jan 10. PubMed PMID: 24387105; PubMed Central PMCID: PMC3988914. 6: Bacolod MD, Lin SM, Johnson SP, Bullock NS, Colvin M, Bigner DD, Friedman HS. The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. Curr Cancer Drug Targets. 2008 May;8(3):172-9. PubMed PMID: 18473730; PubMed Central PMCID: PMC3633091. 7: Liang J, Huang M, Duan W, Yu XQ, Zhou S. Design of new oxazaphosphorine anticancer drugs. Curr Pharm Des. 2007;13(9):963-78. Review. PubMed PMID: 17430192. 8: Patzer L, Hernando N, Ziegler U, Beck-Schimmer B, Biber J, Murer H. Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells. Kidney Int. 2006 Nov;70(10):1725-34. Epub 2006 Sep 27. PubMed PMID: 17003823. 9: Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, Duan W, Zhu YZ. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev. 2005;37(4):611-703. Review. PubMed PMID: 16393888. 10: Jain M, Fan J, Baturay NZ, Kwon CH. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines. J Med Chem. 2004 Jul 15;47(15):3843-52. PubMed PMID: 15239662. 11: Dieckhaus CM, Santos WL, Sofia RD, Macdonald TL. The chemistry, toxicology, and identification in rat and human urine of 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one: a reactive metabolite in felbamate bioactivation. Chem Res Toxicol. 2001 Aug;14(8):958-64. PubMed PMID: 11511169. 12: Ichikawa T, Petros WP, Ludeman SM, Fangmeier J, Hochberg FH, Colvin OM, Chiocca EA. Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res. 2001 Feb 1;61(3):864-8. PubMed PMID: 11221871. 13: Zimmermann J, Bauer HH, Hohorst HJ, Voelcker G. Synthesis of 1-aldofosfamide-perhydrothiazines. Arzneimittelforschung. 2000 Sep;50(9):843-7. PubMed PMID: 11050703. 14: Belfayol-Pisanté L, Guillevin L, Tod M, Fauvelle F. Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitis. Fundam Clin Pharmacol. 2000 Jul-Aug;14(4):415-21. PubMed PMID: 11030450. 15: Giorgianni F, Bridson PK, Sorrentino BP, Pohl J, Blakley RL. Inactivation of aldophosphamide by human aldehyde dehydrogenase isozyme 3. Biochem Pharmacol. 2000 Aug 1;60(3):325-38. PubMed PMID: 10856427. 16: Voelcker G, Pfeiffer B, Schnee A, Hohorst H. Increased antitumour activity of mesyl-I-aldophosphamide-perhydrothiazine, in vivo but not in vitro, compared to I-aldophosphamide-perhydrothiazine. J Cancer Res Clin Oncol. 2000 Feb;126(2):74-8. PubMed PMID: 10664245. 17: Ludeman SM. The chemistry of the metabolites of cyclophosphamide. Curr Pharm Des. 1999 Aug;5(8):627-43. Review. PubMed PMID: 10469895. 18: Tsukamoto N, Chen J, Yoshida A. Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells. Blood Cells Mol Dis. 1998 Jun;24(2):231-8. PubMed PMID: 9714700. 19: Voelcker G, Hohorst HJ. Structure/activity studies with thiazolidinyl- and perhydrothiazinylphosphamide ester. J Cancer Res Clin Oncol. 1998;124(6):297-300. PubMed PMID: 9692835. 20: Joqueviel C, Martino R, Gilard V, Malet-Martino M, Canal P, Niemeyer U. Urinary excretion of cyclophosphamide in humans, determined by phosphorus-31 nuclear magnetic resonance spectroscopy. Drug Metab Dispos. 1998 May;26(5):418-28. PubMed PMID: 9571223.